Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only Get Premium

ETNB 89bio Inc

Price (delayed)

$7.775

Market cap

$1.14B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$3.41

Enterprise value

$857.21M

89bio is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases. The company's lead product candidate, BIO89-100, is ...

Highlights
The equity has soared by 51% since the previous quarter and by 19% year-on-year
89bio's quick ratio has increased by 38% from the previous quarter and by 15% YoY
ETNB's EPS has dropped by 70% year-on-year but it is up by 2.8% since the previous quarter
The company's net income has shrunk by 134% YoY and by 5% QoQ
89bio's debt has increased by 38% YoY

Key stats

What are the main financial stats of ETNB
Market
Shares outstanding
145.98M
Market cap
$1.14B
Enterprise value
$857.21M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1.87
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
Gross profit
$0
Operating income
-$403.29M
Net income
-$386.67M
EBIT
-$380.25M
EBITDA
-$379.5M
Free cash flow
-$399.93M
Per share
EPS
-$3.41
EPS diluted
-$3.41
Free cash flow per share
-$2.73
Book value per share
$4.15
Revenue per share
$0
TBVPS
$4.68
Balance sheet
Total assets
$685.03M
Total liabilities
$79.57M
Debt
$37.58M
Equity
$605.46M
Working capital
$645.06M
Liquidity
Debt to equity
0.06
Current ratio
18.03
Quick ratio
16.86
Net debt/EBITDA
0.73
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-70.2%
Return on equity
-81.4%
Return on invested capital
-105.3%
Return on capital employed
-58.8%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ETNB stock price

How has the 89bio stock price performed over time
Intraday
1.77%
1 week
0.97%
1 month
32%
1 year
-13.32%
YTD
-0.58%
QTD
6.95%

Financial performance

How have 89bio's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$403.29M
Net income
-$386.67M
Gross margin
N/A
Net margin
N/A
ETNB financials
The company's net income has shrunk by 134% YoY and by 5% QoQ
The company's operating income has shrunk by 124% YoY and by 4.8% QoQ

Price vs fundamentals

How does ETNB's price correlate with its fundamentals
Price vs fundamentals
Earnings waterfall
Price vs fair value

Growth

What is 89bio's growth rate over time
ETNB growth chart

Valuation

What is 89bio stock price valuation
P/E
N/A
P/B
1.87
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Valuation vs average
Price to earnings (P/E)
ETNB's EPS has dropped by 70% year-on-year but it is up by 2.8% since the previous quarter
Price to book (P/B)
The equity has soared by 51% since the previous quarter and by 19% year-on-year
The stock's price to book (P/B) is 15% less than its 5-year quarterly average of 2.2
Price to sales (P/S)

Efficiency

How efficient is 89bio business performance
89bio's return on equity has shrunk by 134% YoY
ETNB's return on assets has dropped by 126% year-on-year
The ROIC has plunged by 81% YoY and by 3.8% from the previous quarter

Dividends

What is ETNB's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ETNB.

Financial health

How did 89bio financials performed over time
Assets vs liabilities
ETNB's total assets is up by 43% since the previous quarter and by 19% year-on-year
89bio's quick ratio has increased by 38% from the previous quarter and by 15% YoY
Debt vs equity
89bio's debt is 94% lower than its equity
The equity has soared by 51% since the previous quarter and by 19% year-on-year
89bio's debt has increased by 38% YoY
Balance sheet

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.